Tambotatug pelitecan
Antibody–drug conjugate
Also known as YL201, RG6919
Evidence outlook
Small Cell Lung Cancer: topline reported 2026-09-13
The sponsor reported topline results on 2026-09-13 (Phase 3 TAISHAN-302 (NCT06612151) met its overall survival primary endpoint at interim analysis). The announcement is listed under Regulatory events.
Latest reported trial: TAISHAN-302 (NCT06612151) · Phase 3 · met primary endpoint · grade pending
Also in development:Non-Small Cell Lung Cancer · Phase 1/2Nasopharyngeal Carcinoma · Phase 3Esophageal Squamous Cell Carcinoma · Phase 3Pancreatic Ductal Adenocarcinoma · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
TAISHAN-302 NCT06612151 · Small Cell Lung Cancer Caveat: this result is taken from a company announcement (Roche, 13 September 2026, reporting its collaborator MediLink's interim results), not from the trial registry. A peer-reviewed paper (NEJM) is reported but was not yet found in PubMed. Registry: NCT06612151 | 3 | Overall survival, YL201 vs topotecan, in relapsed small cell lung cancer 2027-12-01 | Overall survival (single primary, interim analysis), YL201 (n=225) vs topotecan (n=226): median 13.3 vs 9.4 months, stratified HR 0.46 (95% CI 0.35 to 0.62), p < 0.0001. Secondary: median PFS 7.4 vs 2.8 months, HR 0.29 (95% CI 0.23 to 0.37); confirmed ORR 59.1% vs 9.7% (Roche release of MediLink data, 13 September 2026). | not yet graded | link ↗ |
View 1 more trial
NCT07739758 NCT07739758 · SCLC Registry: NCT07739758 | 3 | Overall survival (OS) (Up to approximately 5 years); Progression-free survival (PFS) as assessed by BIRC (Up to approximately 30 months) 2029-06 | In progress: results expected 1 Jun 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1/2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other B7-H3 drugs
7MW3711, Elfetabart drozuntecan, Ifinatamab Deruxtecan, Risvutatug rezetecan, 177Lu-BetaBart and 1 more. Compare all 7 B7-H3 drugs
6 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Esophageal Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tambotatug Pelitecan: this drug | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT03189719: Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). NCT02564263: Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181). | |
| Tislelizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed | |
| Ifinatamab Deruxtecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Risvutatug Rezetecan | Phase 3 | Antibody–drug conjugate | B7-H3 | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab | Phase 2 | Multispecific antibody | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2 | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tambotatug pelitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (6)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
April 2027 (2)
2028 (3)
February 2028 (1)
What to watch
April 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (2)
2031 (1)
June 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent